tbuckley/cabot-search huggingface dataset:
Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity
Authors: Emanuela Teveroni, Marsha Pellegrino, Sabrina Sacconi, Patrizia Calandra, Isabella Cascino, Stefano Farioli-Vecchioli, Angela Puma, Matteo Garibaldi, Roberta Morosetti, Giorgio Tasca, Enzo Ricci, Carlo Pietro Trevisan, Giuliana Galluzzi, Alfredo Pontecorvi, Marco Crescenzi, Giancarlo Deidda, Fabiola Moretti
Journal: Journal of Clinical Investigation (2017)

Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant neuromuscular disorder that is characterized by extreme variability in symptoms, with females being less severely affected than males and presenting a higher proportion of asymptomatic carriers. The sex-related factors involved in the disease are not known. Here, we have utilized myoblasts isolated from FSHD patients (FSHD myoblasts) to investigate the effect of estrogens on muscle properties. Our results demonstrated that estrogens counteract the differentiation impairment of FSHD myoblasts without affecting cell proliferation or survival. Estrogen effects are mediated by estrogen receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity of double homeobox 4 (DUX4), a protein whose aberrant expression has been implicated in FSHD pathogenesis. During myoblast differentiation, we observed that the levels and activity of DUX4 increased progressively and were associated with its enhanced recruitment in the nucleus. ERβ interfered with this recruitment by relocalizing DUX4 in the cytoplasm. This work identifies estrogens as a potential disease modifier that underlie sex-related differences in FSHD by protecting against myoblast differentiation impairments in this disease.
High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.
Authors: Anna Vanazzi, Pierfrancesco Ferrucci, Mahila Ferrari, Liliana Calabrese, Marta Cremonesi, Mirco Bartolomei, Giovanni Paganelli, Giovanni Martinelli
Journal: Blood (2005)
Authors’ reply to Beales
Authors: Ben Goldacre, Samuel Whittle, Edzard Ernst, Jonathan Mendel
Journal: BMJ (2017)

Beales argues,1 in response to our paper,2 that trialists should bear responsibility for trials with inappropriate comparators. We agree that trialists should share this responsibility. But about half a million randomised trials have been conducted in medicine to date, involving millions of investigators. These researchers will undoubtedly have heterogeneous skills and conflicts of interest.

Some researchers may lack the key competences to be aware of their ethical breaches. For example, some investigators may be unaware of the need to conduct a systematic review before a trial starts or may regard it as a low priority or may conduct a poor …
Penicillin-Resistant Gonococci
Authors: Meera Sharma, K C Agarwal, B Kumar, S K Sharma
Journal: New England Journal of Medicine (1958)

Minimum inhibitory concentration (MIC) of penicillin was estimated for 25 strains of N. gonorrhoeae, isolated over a period of 10 months (September 1983 June 1984). In 16 d be strains, the MIC of penicillin ranged between 0.01ug/ml and 0.63 ug/ml and all were negative for penicillinase production. In 9 strains, the MIC was 1.25 ug/ml, and 5 of these strains produced penicillinase. Of these 5 penicillinase producing strains, 4 had MIC10 ug/ml and in one it was 2.5 ug/ml.
Abstract P4-03-13: Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis
Authors: L Connelly, N Yadav, A Barcikowski, Y Imaizumi, A Jacobs
Journal: Cancer Research (2017)

Abstract Obese individuals with breast cancer have a poorer prognosis and higher risk of metastatic disease vs. non-obese patients. Prior research has largely focused on defining the interactions between adipocytes and tumor cells, but other cell types may also play a role. Adipose tissue in obese individuals is characterized by a significant infiltration of macrophages. We have therefore investigated the adipocyte-macrophage interaction as a possible mechanism whereby obesity promotes breast cancer metastasis. We performed co-culture with both human and murine cells to determine whether adipocytes influence the expression of metastasis-promoting signals in macrophages. For the human system we co-cultured primary breast adipocytes with THP-1 macrophages. For the murine system we co-cultured 3T3-L1 differentiated adipocytes with J774.1 macrophages. We then assayed the mRNA levels and protein expression of metastasis-promoting genes. In both systems we found that co-culture with adipocytes increased the expression of Vascular Endothelial Growth Factor A (VEGF-A) in macrophages. In examining a potential mechanism, we also show that media collected from cultured adipocytes (adipocyte-conditioned media) activates the transcription factor Egr-1 in macrophages. Since Egr-1 is a known regulator of VEGF-A expression, this is a potential mechanism whereby VEGF-A transcription is up-regulated. Treatment of human macrophages with Interleukin-6, Leptin and Insulin induced VEGF-A levels to a similar degree as co-culture, identifying these as adipocyte-derived signals that can possibly mediate this effect. In summary we have found that the interaction between adipocytes and macrophages leads to the up-regulation of the pro-angiogenic signal VEGF-A in macrophages. Therefore this represents a potential mechanism whereby obesity could promote breast cancer metastasis. Citation Format: Connelly L, Yadav N, Barcikowski A, Imaizumi Y, Jacobs A. Obesity and breast cancer: The adipocyte-macrophage interaction as a mediator of metastasis [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-13.
Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients
Authors: Saravanan Ganesan, Ezhilarasi Chendamarai, Ansu Abu Alex, Sachin David, Giridhara R Jayandharan, Poonkuzhali Balasubramanian, Rayaz Ahmed, Aby Abraham, Auro Viswabandya, Biju George, Alok Srivastava, Vikram Mathews
Journal: Blood (2012)
Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy
Authors: Joël Castelli, Adrien Depeursinge, Berardino de Bari, Anne Devillers, Renaud de Crevoisier, Jean Bourhis, John O. Prior
Journal: Clinical Nuclear Medicine (2017)

In the context of oropharyngeal cancer treated with definitive radiotherapy, the aim of this retrospective study was to identify the best threshold value to compute metabolic tumor volume (MTV) and/or total lesion glycolysis to predict local-regional control (LRC) and disease-free survival.One hundred twenty patients with a locally advanced oropharyngeal cancer from 2 different institutions treated with definitive radiotherapy underwent FDG PET/CT before treatment. Various MTVs and total lesion glycolysis were defined based on 2 segmentation methods: (i) an absolute threshold of SUV (0-20 g/mL) or (ii) a relative threshold for SUVmax (0%-100%). The parameters' predictive capabilities for disease-free survival and LRC were assessed using the Harrell C-index and Cox regression model.Relative thresholds between 40% and 68% and absolute threshold between 5.5 and 7 had a similar predictive value for LRC (C-index = 0.65 and 0.64, respectively). Metabolic tumor volume had a higher predictive value than gross tumor volume (C-index = 0.61) and SUVmax (C-index = 0.54). Metabolic tumor volume computed with a relative threshold of 51% of SUVmax was the best predictor of disease-free survival (hazard ratio, 1.23 [per 10 mL], P = 0.009) and LRC (hazard ratio: 1.22 [per 10 mL], P = 0.02).The use of different thresholds within a reasonable range (between 5.5 and 7 for an absolute threshold and between 40% and 68% for a relative threshold) seems to have no major impact on the predictive value of MTV. This parameter may be used to identify patient with a high risk of recurrence and who may benefit from treatment intensification.
Treatment of Chronic Arterial Occlusions with Streptokinase
Authors: H. Poliwoda, K. Alexander, V. Buhl, D. Hülsten, H. H. Wagner
Journal: New England Journal of Medicine (1969)

Of 27 patients with long standing arterial occlusions treated with streptokinase, reconstitution of flow in the external iliac and femoral arteries occurred in 17, confirming an earlier report that fibrinolytic therapy with streptokinase may be useful in such cases. The important practical implication is that there may be a large number of patients (in whom it was formerly considered that fibrinolytic therapy would not be effective) who could benefit from such therapy.
Cytokine-induced differentiation of multipotent adult progenitor cells into functional smooth muscle cells
Authors: J. J. Ross, Z. Hong, B. Willenbring, L. Zeng, B. Isenberg, E. H. Lee, M. Reyes, S. A. Keirstead, E. K. Weir, R. T. Tranquillo, C. M. Verfaillie
Journal: Journal of Clinical Investigation (2007)

During the preparation of the manuscript, the primer sequences for rat Flt1 and swine SMaActin were incorrectly reported in the supplemental
Cyclin-Dependent Kinase Inhibitors Enhance Sensitivity to Methotrexate In Human T-Cell Leukemia Jurkat Cells
Authors: Hitoji Uchiyama, Yoshihiro Sowa, Miki Wakada, Mayumi Yogosawa, Ryoko Nakanishi, Mano Horinaka, Chihiro Shimazaki, Masafumi Taniwaki, Toshiyuki Sakai
Journal: Blood (2010)
A Phase I Dose Escalation Trial of Donor T Cells Sensitized with Pentadecapeptides of the CMV-pp65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants.
Authors: Guenther Koehne, Ekaterina Doubrovina, Aisha Hasan, Juliet Barker, H.R. Castro-Malaspina, Miguel Perales, Ann Jakubowski, Esperanza B Papadopoulos, James W. Young, Farid Boulad, Trudy N Small, Susan E Prockop, Nancy A. Kernan, Andromachi Scaradavou, Genovefa Papanicolaou, Marcel van den Brink, Richard J O'Reilly
Journal: Blood (2009)
<i>Notes from the Field:</i> Hepatitis C Transmission from Inappropriate Reuse of Saline Flush Syringes for Multiple Patients in an Acute Care General Hospital — Texas, 2015
Authors: Sandi Arnold, Sharon K. Melville, Bonnie Morehead, Gilberto Vaughan, Anne Moorman, Matthew B. Crist
Journal: MMWR Morbidity and Mortality Weekly Report (2017)
One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction
Authors: Enrico Fabris, Sinem Kilic, Arnoud W. J. van’t Hof, Jurrien ten Berg, Ana Ayesta, Uwe Zeymer, Martial Hamon, Louis Soulat, Debra Bernstein, Prodromos Anthopoulos, Efthymios N. Deliargyris, Philippe Gabriel Steg
Journal: JAMA Cardiology (2017)

Uncertainty exists regarding potential survival benefits of bivalirudin compared with heparin with routine or optional use of glycoprotein IIb/IIIa inhibitors (GPIs) in patients with ST-segment elevation myocardial infarction (STEMI). Few data are available regarding long-term mortality in the context of contemporary practice with frequent use of radial access and novel platelet adenosine diphosphate P2Y12 receptor inhibitors.To assess the effect of bivalirudin monotherapy compared with unfractionated or low-molecular-weight heparin plus optional GPIs on 1-year mortality.This international, randomized, open-label clinical trial (EUROMAX [European Ambulance Acute Coronary Syndrome Angiography]) included 2198 patients with STEMI undergoing transport for primary percutaneous coronary intervention from March 10, 2010, through June 20, 2013, and followed up for 1 year. Patients were randomized (1:1) in ambulance to bivalirudin monotherapy vs unfractionated or low-molecular-weight heparin plus optional GPIs (control group). Analysis was based on intention to treat.The primary outcome of this prespecified analysis was 1-year mortality. All deaths were adjudicated as cardiac or noncardiac by an independent, blinded clinical events committee. One-year mortality was assessed and examined across multiple prespecified subgroups.Of the 2198 patients enrolled (1675 men [76.2%] and 523 women [23.8%]; median [interquartile range] age, 62 [52-72] years), complete 1-year follow-up data were available for 2164 (98.5%). All-cause 1-year mortality occurred in 118 patients (5.4%). The number of all-cause deaths was the same for both treatment groups (59 deaths; relative risk [RR], 1.02; 95% CI, 0.72-1.45; P = .92). No differences were noted in the rates of 1-year cardiac death (44 [4.0%] for the bivalirudin group vs 48 [4.3%] for the control group; RR, 0.93; 95% CI, 0.63-1.39; P = .74) or noncardiac death (15 [1.4%] for the bivalirudin group vs 11 [1.0%] for the control group; RR, 1.39; 95% CI, 0.64-3.01; P = .40). Results were consistent across the prespecified patient subgroups. The rate of deaths occurring from 30 days to 1 year was also similar (27 [2.5%] in the bivalirudin group vs 25 [2.3%] in the control group; RR, 1.10; 95% CI, 0.64-1.88; P = .73).In patients with STEMI who were being transported for primary percutaneous coronary intervention, treatment with bivalirudin or with heparin with optional use of GPI resulted in similar 1-year mortality. The reduced composite end point of death and/or major bleeding at 30 days in the bivalirudin arm of the EUROMAX trial did not translate into reduced cardiovascular or all-cause death at 1 year.clinicaltrials.gov Identifier: NCT01087723.
Pituitary Carcinoma in a Patient with an SDHB Mutation
Authors: Nicola Tufton, Federico Roncaroli, Irene Hadjidemetriou, Mary N Dang, Judit Dénes, Leonardo Guasti, Maria Thom, Michael Powell, Stephanie E Baldeweg, Naomi Fersht, Márta Korbonits
Journal: Endocrine Pathology (2017)

We present the first case of pituitary carcinoma occurring in a patient with a succinate dehydrogenase subunit B (SDHB) mutation and history of paraganglioma. She was initially treated for a glomus tumour with external beam radiotherapy. Twenty-five years later, she was diagnosed with a non-functioning pituitary adenoma, having developed bitemporal hemianopia. Recurrence of the pituitary lesion (Ki-67 10% and p53 overexpressed) occurred 5 years after her transsphenoidal surgery, for which she underwent two further operations followed by radiotherapy. Histology showed large cells with vacuolated clear cytoplasm with positive immunostaining for steroidogenic factor 1 (SF1) and negative staining for pituitary hormones. Four years after the pituitary radiotherapy, two metastatic deposits were identified: a foramen magnum lesion and an intradural extra-medullary cervical lesion at the level of C3/C4. There was also significant growth of the primary pituitary lesion with associated visual deterioration. A biopsy of the foramen magnum lesion, demonstrating cells with vacuolated, clear cytoplasm and positive SF1 staining confirmed a pituitary carcinoma, for which she was commenced on temozolomide chemotherapy. There was dramatic clinical improvement after three cycles and reduction in the size of the lesions was observed following six cycles of temozolomide, and further shrinkage after 10 cycles. The plan is for a total of 12 cycles of temozolomide chemotherapy. SDH mutation-related pituitary tumours have an aggressive phenotype which, in this case, led to metastatic disease. SF1 immunostaining was helpful to identify the tissue origin of the metastatic deposit and to confirm the pituitary carcinoma.
OP14. WALTON RESEARCH TISSUE BANK:AN UPDATE
Authors: Mr Khaja Syed
Journal: Neuro-Oncology (2017)

The Walton Research Tissue Bank (WRTB) was established in 2011 to facilitate and promote multidisciplinary basic and translational neuro-oncology research. WRTB gained full approval of the National Research Ethics Service [REC Ref: 11/WNo03/2] and is held under a Human Tissue Authority License at the Walton Centre NHS Foundation Trust. WRTB is been fully supported by Trust Management and facilitated by clinical and pathology staff. Recently, the Walton Research Tissue Bank has successfully received ethics approval (extension) from Wales REC4 for next five years until 2020 [REC Ref: 15/WA/0385]. All patients undergoing surgery at The Walton Centre NHS Foundation Trust are invited to participate in various research studies. With appropriate research consent, tumour tissues along with matched blood samples and clinical data are obtained at surgery as part of routine clinical practice and stored in the Walton Research Tissue Bank. Our current research interests includes chemosensitivity of gliomas, factors that influence progression and recurrence in gliomas, the impact of molecular genetics and radiological parameters on outcome in gliomas and meningiomas, blood-bourne biomarkers and the biology of tumours that metastasise to the brain. Such research involves analysis of DNA, RNA, proteins and metabolites from tumour tissues and blood and in some cases cells from tumours may be cultured in the laboratory. Comparisons between tissue biology, radiological imaging and clinical outcome are an essential component of this research. As a member of Brain Tumour North West (BTNW), the WRTB co-ordinates and supports joint research projects with the Brain Tumour North West Tissue Bank at the Royal Preston Hospital thus enabling greater recruitment to neuro-oncology research especially with low incidence tumour types. This presentation will provide an update on WRTB recruitment, sample collections and research collaborations and also highlighting the vital role of tissue bank in neuro-oncology research.
Curcumin Inhibits Proliferation of Leukemic Cells Expressing P210BCR-ABL or BCR-ABL-T315I and Prolongs Survival of Mice with B-Cell Acute Lymphoblastic Leukemia (B-ALL).
Authors: Basem M. William, Ami Goodrich, Cong Peng, Shaoguang Li
Journal: Blood (2006)
Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,
Authors: Dominika Nowis, Magdalena Winiarska, Jacek Bil, Angelika Muchowicz, Malgorzata Wanczyk, Eliza Glodkowska-Mrowka, Kamil Bojarczuk, Malgorzata Firczuk, Ewa Wilczek, Malgorzata Wachowska, Justyna Chlebowska, Michal Dwojak, Marta Miaczynska, Tomasz Stoklosa, Jakub Golab
Journal: Blood (2011)
The Declining Risk of ABO Incompatibilities: Twelve Years of Hemovigilance in France.
Authors: Philippe Renaudier, Mai Phuong Vo Mai, Sylvie Schlanger, Nadra Ounnoughene, Pascal Breton, Stephane Cheze, Albane Girard, Lisette Hauser, Jean Francois Legras, Danielle Rebibo, Chantal Waller, Bernard Lassale, Cyril Caldani
Journal: Blood (2007)
Functional Alterations of Lin−CD34+CD38+ Progenitors in Chronic Myelomonocytic Leukaemia and on Progression to Acute Leukaemia.
Authors: Qian Sun, Chi-Chiu So, Sze-Fai Yip, Thomas S.K. Wan, Edmond Shiu Kwan Ma, LiChong Chan
Journal: Blood (2007)
Abstract P1-08-08: Identification of tumor-promoting and tumor-inhibiting genes with age dependent expression in breast cancer patients
Authors: X Gu, H Zhu, L Sun
Journal: Cancer Research (2017)

Abstract Age is the number one risk factor for breast cancer development. The breast cancer incidence rate increases with age, following beta distribution, which is approximately linear in range from 30 to 70 years old [1]. Transcriptome alterations have been shown to promote tumorigenesis for many types of cancers. Therefore, we hypothesize that the genes with altered expression during aging may promote breast cancer development and/or progression. Using The Cancer Genome Atlas data, we extracted whole transcriptome profiling data of matched normal tissues from 82 female patients with age at diagnosis and menopausal status available. First, we applied simple linear regression to study the association between gene expression level and age at diagnosis on all the 82 patients. 258 upregulated and 240 downregulated genes are identified, which are associated with age. Secondly, 493 upregulated and 254 downregulated genes are identified that are altered by menopause by comparing post-menopausal to pre-menopausal patients (FDR &amp;lt; 0.05). Exclusion of these menopause affected genes from those genes affected by age (258 upregulated and 240 downregulated) results in 148 upregulated and 189 downregulated genes during aging. Thirdly, by comparing matched tumor and adjacent normal samples, 3356 upregulated and 3124 downregulated genes are found to be associated with tumorigenesis. Overlapping of tumorigenesis associated genes with age dependent genes result in 14 upregulated and 24 downregulated genes that are both age and tumorigenesis associated. This discovery is being validated with normal breast tissues from donors in GTEx cohort. Experimental manipulation of the upregulated genes in seven breast cancer cell lines, representing five subtypes of breast cancer, demonstrated their essential role in promoting tumor malignancy, suggesting the upregulation is not merely passenger event. In a large mixed cohort, this panel of genes have significant predictive value in relapse free survival of breast cancer patients. Funding: CPRIT Research Training Award (RP140105); NIH R01CA192564 Reference: Francesco Pompei and Richard Wilson (2001). Age Distribution of Cancer: The incidence Turnover at Old Age. Human and Ecological Risk Assessment: Vol. 7, No. 6, pp. 1619-1650. Citation Format: Gu X, Zhu H, Sun L. Identification of tumor-promoting and tumor-inhibiting genes with age dependent expression in breast cancer patients [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-08-08.
Is There a Role for Red Cell Mass (RCM) Assessment To Classify Myeloproliferative Disorders (MPD) in the JAK2 Era?.
Authors: Bruno Cassinat, Christelle Laguillier, Claude Gardin, Virginie De Beco, Sara Burcheri, Pierre Fenaux, Christine Chomienne, Jean-Jacques Kiladjian
Journal: Blood (2007)
Caution in Generalizing the Use of Adjunctive Primary Corticosteroids in Kawasaki Disease to Unselected Non-Japanese Populations
Authors: Herney Andrés García-Perdomo, Juan Pablo Calle
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal